|
age
|
sex
|
dosis
|
delay
|
treatment
|
outcome
|
author
|
|---|
|
41
|
f
|
200 mg/m2
|
4 hours
|
HD
|
alive, n.s.
|
Brivet et al.
|
|
36
|
m
|
480 mg/m2
|
6 days
|
HD
|
alive, CRF, hearing loss
|
Schiller et al.
|
|
62
|
m
|
240 mg/m2
|
3 days
|
STS, HD
|
alive, n.a.
|
Delanian et al.
|
|
68
|
f
|
280 mg/m2
|
12 days
|
PPH, HD
|
alive, CRF, hearing loss
|
Chu et al.
|
|
54
|
f
|
205 mg/m2
|
6 days
|
HD
|
alive, n.a.
|
Lagrange et al.
|
|
59
|
m
|
300 mg/m2
|
3 days
|
PPH
|
alive, n.s.
|
Jung et al.
|
|
38
|
f
|
total 640 mg
|
4 days
|
NAC
|
dead
|
Sheik-Hamad et al.
|
|
14
|
f
|
360 mg/m2
|
70 hours
|
STS
|
alive, hearing loss
|
Erdlenbruch et al.
|
|
48
|
m
|
400 mg/m2
|
no delay
|
PPH, HD
|
alive, n.s.
|
Choi et al.
|
|
63
|
m
|
total 750 mg
|
no delay
|
HD, NAC, PPH
|
dead
|
Charlier et al.
|
- HD: hemodialysis; STS: sodium thiosulfate; PPH: plasmapheresis; NAC: N-acetylcysteine; w.s.: with sequelae; n.s.: no sequelae; n.a.: not applicable; CRF: chronic renal failure
